Literature DB >> 33423140

A probable means to an end: exploring P131 pharmacophoric scaffold to identify potential inhibitors of Cryptosporidium parvum inosine monophosphate dehydrogenase.

Kehinde F Omolabi1, Emmanuel A Iwuchukwu1, Clement Agoni1, Fisayo A Olotu1, Mahmoud E S Soliman2.   

Abstract

Compound P131 has been established to inhibit Cryptosporidium parvum's inosine monophosphate dehydrogenase (CpIMPDH). Its inhibitory activity supersedes that of paromomycin, which is extensively used in treating cryptosporidiosis. Through the per-residue energy decomposition approach, crucial moieties of P131 were identified and subsequently adopted to create a pharmacophore model for virtual screening in the ZINC database. This search generated eight ADMET-compliant hits that were examined thoroughly to fit into the active site of CpIMPDH via molecular docking. Three compounds ZINC46542062, ZINC58646829, and ZINC89780094, with favorable docking scores of - 8.3 kcal/mol, - 8.2 kcal/mol, and - 7.5 kcal/mol, were selected. The potential inhibitory mechanism of these compounds was probed using molecular dynamics simulation and Molecular Mechanics Generalized Poisson Boltzmann Surface Area (MM/PBSA) analyses. Results revealed that one of the hits (ZINC46542062) exhibited a lower binding free energy of - 39.52 kcal/mol than P131, which had - 34.6 kcal/mol. Conformational perturbation induced by the binding of the identified hits to CpIMPDH was similar to P131, suggesting a similarity in inhibitory mechanisms. Also, in silico investigation of the properties of the hit compounds implied superior physicochemical properties with regards to their synthetic accessibility, lipophilicity, and number of hydrogen bond donors and acceptors in comparison with P131. ZINC46542062 was identified as a promising hit compound with the highest binding affinity to the target protein and favorable physicochemical and pharmacokinetic properties relative to P131. The identified compounds can serve as a basis for conducting further experimental investigations toward the development of anticryptosporidials, which can overcome the challenges of existing therapeutic options. Graphical abstract P131 and the identified compounds docked in the NAD+ binding site of Cryptosporidium parvum IMPDH.

Entities:  

Keywords:  ADMET; Cryptosporidium parvum IMPDH; MM/PBSA; P131; Per-residue energy decomposition; Virtual screening

Year:  2021        PMID: 33423140     DOI: 10.1007/s00894-020-04663-3

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  70 in total

1.  Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections.

Authors:  M Amenta; E R Dalle Nogare; C Colomba; T S Prestileo; F Di Lorenzo; S Fundaro; A Colomba; A Ferrieri
Journal:  J Chemother       Date:  1999-10       Impact factor: 1.714

2.  Longitudinal study of Cryptosporidium infection in children in northeastern Brazil.

Authors:  R D Newman; C L Sears; S R Moore; J P Nataro; T Wuhib; D A Agnew; R L Guerrant; A A Lima
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

3.  Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus.

Authors:  P Hicks; R J Zwiener; J Squires; V Savell
Journal:  J Pediatr       Date:  1996-08       Impact factor: 4.406

4.  Combination drug therapy for cryptosporidiosis in AIDS.

Authors:  N H Smith; S Cron; L M Valdez; C L Chappell; A C White
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

5.  Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. parvum serum immunoglobulin G.

Authors:  C L Chappell; P C Okhuysen; C R Sterling; C Wang; W Jakubowski; H L Dupont
Journal:  Am J Trop Med Hyg       Date:  1999-01       Impact factor: 2.345

Review 6.  Burden of disease from cryptosporidiosis.

Authors:  Debbie-Ann T Shirley; Shannon N Moonah; Karen L Kotloff
Journal:  Curr Opin Infect Dis       Date:  2012-10       Impact factor: 4.915

7.  Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.

Authors:  Karen L Kotloff; James P Nataro; William C Blackwelder; Dilruba Nasrin; Tamer H Farag; Sandra Panchalingam; Yukun Wu; Samba O Sow; Dipika Sur; Robert F Breiman; Abu Sg Faruque; Anita Km Zaidi; Debasish Saha; Pedro L Alonso; Boubou Tamboura; Doh Sanogo; Uma Onwuchekwa; Byomkesh Manna; Thandavarayan Ramamurthy; Suman Kanungo; John B Ochieng; Richard Omore; Joseph O Oundo; Anowar Hossain; Sumon K Das; Shahnawaz Ahmed; Shahida Qureshi; Farheen Quadri; Richard A Adegbola; Martin Antonio; M Jahangir Hossain; Adebayo Akinsola; Inacio Mandomando; Tacilta Nhampossa; Sozinho Acácio; Kousick Biswas; Ciara E O'Reilly; Eric D Mintz; Lynette Y Berkeley; Khitam Muhsen; Halvor Sommerfelt; Roy M Robins-Browne; Myron M Levine
Journal:  Lancet       Date:  2013-05-14       Impact factor: 79.321

8.  Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural, and dynamic properties that can be exploited for drug design.

Authors:  Nwakaso N Umejiego; Catherine Li; Thomas Riera; Lizbeth Hedstrom; Boris Striepen
Journal:  J Biol Chem       Date:  2004-07-21       Impact factor: 5.157

9.  A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply.

Authors:  W R Mac Kenzie; N J Hoxie; M E Proctor; M S Gradus; K A Blair; D E Peterson; J J Kazmierczak; D G Addiss; K R Fox; J B Rose
Journal:  N Engl J Med       Date:  1994-07-21       Impact factor: 91.245

Review 10.  Cryptosporidiosis: A mini review.

Authors:  K Vanathy; Subhash Chandra Parija; Jharna Mandal; Abdoul Hamide; Sriram Krishnamurthy
Journal:  Trop Parasitol       Date:  2017 Jul-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.